Increased Intrahepatic Expression of Immune Checkpoint Molecules in Autoimmune Liver Disease

Cells. 2021 Oct 6;10(10):2671. doi: 10.3390/cells10102671.

Abstract

Immune checkpoint molecules (ICM) are critical in maintaining immunologic homeostasis and participate in preventing or promoting autoimmune disease development. Exploring a large panel of intrahepatic inhibitory and stimulatory ICM is necessary for drawing a general picture of the immune alterations in autoimmune hepatitis (AIH). Here, we performed a multiparametric analysis of ICM, including PD-1, TIM3, LAG3, CTLA-4, OX40 and 4-1BB, and we determined their expression on intrahepatic lymphocyte subsets in untreated and in treated patients with AIH in comparison to normal liver tissue. AIH patient-derived liver tissue revealed the overexpression of ICM, mainly PD-1 and 4-1BB, as well as the strong correlation between PD-1+ CD8+ T-cell abundance and severity of AIH (alanine transaminase and aspartate transaminase levels). Our results show that the ICM play an important role in the loss of immune homeostasis in the liver, providing an attractive approach to investigate their role as targets for effective therapeutic interventions.

Keywords: 4-1BB; PD-1; autoimmune hepatitis; autoimmune liver disease; immune checkpoint molecules.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Autoimmune Diseases / immunology*
  • Autoimmune Diseases / metabolism
  • Biomarkers / metabolism
  • CD8-Positive T-Lymphocytes / immunology
  • Female
  • Humans
  • Immune Checkpoint Proteins / metabolism*
  • Liver / metabolism*
  • Liver / pathology
  • Liver Diseases / immunology*
  • Liver Diseases / metabolism
  • Lymphocytes / metabolism
  • Male
  • Middle Aged
  • Models, Biological

Substances

  • Biomarkers
  • Immune Checkpoint Proteins